Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials.

Lori-Ann LinkinsGeorge HuTheodore Earl Warkentin

Published in: Research and practice in thrombosis and haemostasis (2018)

Fondaparinux appears to be an effective and safe anticoagulant for treatment of acute HIT despite the absence of randomized trials. Caution should exercised when using fondaparinux in patients with renal insufficiency.

Keyphrases

systematic review
meta analyses
venous thromboembolism
randomized controlled trial
drug induced
liver failure
atrial fibrillation
high glucose
diabetic rats
respiratory failure
growth factor
clinical trial
aortic dissection
hepatitis b virus
extracorporeal membrane oxygenation
mechanical ventilation